DXCM - DexCom Inc Stock Price, Fair Value and News

$79.97+0.62 (+0.78%)

Delayed as of 03 Dec 2024, 11:40 am ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

DXCM Price Action

Last 7 days

2.0%

Last 30 days

12.8%

Last 90 days

9.7%

Trailing 12 Months

-32.0%

DXCM RSI Chart

DXCM Valuation

Market Cap

31.0B

Price/Earnings (Trailing)

45.53

Price/Sales (Trailing)

7.84

EV/EBITDA

31.76

Price/Free Cashflow

57.93

DXCM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

DXCM Fundamentals

DXCM Revenue

Revenue (TTM)

4.0B

Rev. Growth (Yr)

1.97%

Rev. Growth (Qtr)

-1.01%

DXCM Earnings

Earnings (TTM)

680.8M

Earnings Growth (Yr)

11.52%

Earnings Growth (Qtr)

-6.2%

DXCM Profitability

Operating Margin

95.07%

EBT Margin

18.81%

Return on Equity

34.4%

Return on Assets

10.71%

Free Cashflow Yield

1.73%

DXCM Investor Care

Shares Dilution (1Y)

1.09%

Diluted EPS (TTM)

1.66

DXCM Alerts

2 major insider sales recently.

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	3.8B	3.9B	4.0B	0
2023	3.0B	3.2B	3.4B	3.6B
2022	2.6B	2.7B	2.8B	2.9B
2021	2.0B	2.2B	2.3B	2.4B
2020	1.6B	1.7B	1.8B	1.9B
2019	1.1B	1.2B	1.4B	1.5B
2018	760.6M	832.5M	914.6M	1.0B
2017	599.4M	632.7M	668.7M	718.5M
2016	445.4M	489.8M	534.2M	573.3M
2015	285.1M	319.2M	354.4M	402.0M
2014	177.1M	200.1M	226.2M	259.0M
2013	109.5M	121.8M	141.6M	160.0M
2012	82.2M	84.3M	89.1M	100.0M
2011	53.3M	62.9M	69.5M	76.3M
2010	34.4M	39.2M	43.9M	48.6M
2009	0	0	0	29.7M

Get all data in R, Python etc through our Historical Stock Data APIs

About DexCom Inc

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

CEO	Mr. Kevin Ronald Sayer
WEBSITE	dexcom.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	7500

DexCom Inc Frequently Asked Questions

What is the ticker symbol for DexCom Inc? What does DXCM stand for in stocks?

DXCM is the stock ticker symbol of DexCom Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of DexCom Inc (DXCM)?

As of Mon Dec 02 2024, market cap of DexCom Inc is 30.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DXCM stock?

You can check DXCM's fair value in chart for subscribers.

Is DexCom Inc a good stock to buy?

The fair value guage provides a quick view whether DXCM is over valued or under valued. Whether DexCom Inc is cheap or expensive depends on the assumptions which impact DexCom Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DXCM.

What is DexCom Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Dec 02 2024, DXCM's PE ratio (Price to Earnings) is 45.53 and Price to Sales (PS) ratio is 7.84. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DXCM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on DexCom Inc's stock?

In the past 10 years, DexCom Inc has provided 0.191 (multiply by 100 for percentage) rate of return.